CJC-1295 (no DAC)
GHRH analog (investigational) · Pre-filled pen
CJC-1295 without DAC (Mod-GRF 1-29) is a modified fragment of growth-hormone-releasing hormone. It is understood to bind GHRH receptors on the anterior pituitary and to prompt pulsatile release of endogenous growth hormone, which may in turn influence IGF-1 signalling. Without the Drug Affinity Complex its action is short-lived, so it is investigated as a pulse secretagogue rather than a sustained one. Human evidence remains limited and the mechanism is drawn largely from GHRH-analog research.
Studied use areas
- Investigated for growth-hormone / IGF-1 axis support
- Studied within lean-mass and recovery research
- Explored for body-composition and sleep-quality signalling
- Researched alongside other GH secretagogues in the GH-axis literature
Safety & status
- Investigational; robust human safety data are limited
- Use only under qualified physician supervision
- Prohibited in competitive sport: listed under WADA Prohibited List class S2 (peptide hormones, growth factors, related substances and mimetics — GHRH analogues, where CJC-1295 is named)
- Not for use in pregnancy or breastfeeding, or with active or suspected malignancy (GH/IGF-1 axis considerations)
⚕ Clinical note: CJC-1295 (no DAC) is an investigational, research-grade peptide and not an approved medicine. It is intended for physician-directed use only, and this content is educational, not medical advice.
Evidence: Grade D — investigational; essentially no peer-reviewed human data for the no-DAC form (evidence extrapolated from GHRH-analogue research) · References: Jetté et al., Endocrinology 2005 (origin of the tetrasubstituted GRF(1-29) backbone; the study itself characterises the albumin-binding DAC conjugate in rats); Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006 (CJC-1295 with DAC — related long-acting analogue, not this product); Dominikowski et al., Frontiers in Endocrinology 2026 (evidence review of GH-axis peptides); Sigalos & Pastuszak, Sexual Medicine Reviews 2018
